Autoimmune Thyroid Disease and Pregnancy Medication
- Author: Dotun A Ogunyemi, MD; Chief Editor: George T Griffing, MD more...
The goals of pharmacotherapy are to reduce morbidity and to prevent complications.
ATDs are effective, reversible treatments for hyperthyroidism. The consensus among experts is that ATDs should be first-line treatments for pregnant women with hyperthyroidism. ATDs inhibit iodination of thyroid thyroglobulin and thyroglobulin synthesis by competing with iodine for peroxidase. PTU and MMI are available in the United States. PTU and MMI are equally effective.
Both PTU and MMI cross the placenta and can cause fetal hypothyroidism and goiter. In addition, both PTU and MMI are excreted in small amounts in breast milk. MMI is not bound to plasma protein as much as PTU; therefore, it is excreted into the breast milk in slightly higher concentrations than PTU is.
Derivative of thiourea that inhibits organification of iodine by thyroid gland. Blocks oxidation of iodine in thyroid gland, inhibiting thyroid hormone synthesis. Inhibits T4-to-T3 conversion (advantage over other agents). DOC in patients with hyperthyroidism during pregnancy because of reports of fetal aplasia cutis (reversible scalp defect) in association with MMI or CMI. Taper gradually to minimum dosage required to maintain clinical euthyroid and to avoid fetal hypothyroidism.
Inhibits thyroid hormone by blocking oxidation of iodine in thyroid gland, but not known to inhibit peripheral conversion of thyroid hormone. Taper gradually to minimum dosage required to maintain clinical euthyroid and to avoid fetal hypothyroidism. Cases of fetal aplasia cutis reported.
Iodides inhibit the release of stored thyroid hormones. They decrease serum T4 and T3 concentrations by 30-50% by the 10th day of treatment. Iodides are reserved for the treatment of severe thyrotoxicosis or for preoperative treatment in combination with ATDs and beta-blockers. These agents readily cross the placenta by the 12th week of gestation and are readily taken up by the fetal thyroid gland. Long-term use of iodides can lead to fetal hypothyroidism and goiter. In pregnant women, these drugs should generally be used for no longer than 2 weeks.
DOC. Rapidly inhibits release of thyroid hormones by directly affecting thyroid gland. Inhibits synthesis of thyroid hormones. Also appears to attenuate cyclic adenosine monophosphate (cAMP)–mediated effects of TSH.
Several forms of thyroid hormones are commercially available. They include levothyroxine, liothyronine, and liotrix. Levothyroxine is the DOC for treating pregnant women with hypothyroidism. No conclusive evidence supports the use of levothyroxine to prevent perinatal hypothyroidism.
Levo isomer of T4. Once absorbed, T4 deiodinated to T3 in extrathyroidal tissues. First choice in treatment of hypothyroidism during pregnancy because it mimics physiologic state. Measure TSH levels q4wk, and adjust dosage.
Beta-blockers are valuable adjunct to ATDs. These drugs are effective for alleviating symptoms of hypermetabolic state (eg, palpitation, sweating, nervousness, tremor). They are safe during pregnancy to achieve immediate control of symptomatic thyrotoxicosis. The goal of beta-blockage is to reduce the mother's heart rate to less than 100 bpm. Prolonged use of beta-blockers has been associated with intrauterine growth restriction, fetal bradycardia, hypoglycemia, and an abnormal response to stress; therefore, long-term use not recommended during pregnancy.
DOC in treating cardiac arrhythmias resulting from hyperthyroidism. Controls cardiac and psychomotor manifestations in minutes.
Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007 Aug. 92(8 Suppl):S1-47. [Medline].
Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011 Oct. 21(10):1081-125. [Medline]. [Full Text].
McGiven AR, Adams DD, Purves HD. A comparison of the heat stability of long-acting thyroid stimulator and human thyroid-stimulating hormone. J Endocrinol. 1965 Apr. 32:29-33. [Medline].
Adams DD, Kennedy TH, Purves HD, Siret NE. Failure of TSH antisera to neutralize long-acting thyroid stimulator. Endocrinology. 1962 Jun. 70:801-5. [Medline].
Adams DD. The presence of an abnormal thyroid-stimulating hormone in the serum of some thyrotoxic patients. J Clin Endocrinol Metab. 1958 Jul. 18(7):699-712. [Medline].
Adams DD. The pathogenesis of thyrotoxicosis the discovery of LATS. N Z Med J. 1975 Jan 8. 81(531):15-7. [Medline].
Wilson KL, Casey BM, McIntire DD, Halvorson LM, Cunningham FG. Subclinical thyroid disease and the incidence of hypertension in pregnancy. Obstet Gynecol. 2012 Feb. 119(2 Pt 1):315-20. [Medline].
Friedrich N, Schwarz S, Thonack J, John U, Wallaschofski H, Völzke H. Association between parity and autoimmune thyroiditis in a general female population. Autoimmunity. 2008 Mar. 41(2):174-80. [Medline].
Brent GA. Maternal thyroid function: interpretation of thyroid function tests in pregnancy. Clin Obstet Gynecol. 1997 Mar. 40(1):3-15. [Medline].
FDA MedWatch Safety Alerts for Human Medical Products. Propylthiouracil (PTU). US Food and Drug Administration. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm164162.htm. Accessed: June 3, 2009.
ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid disease in pregnancy. Obstet Gynecol. 2002 Aug. 100(2):387-96. [Medline].
Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR. Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism. N Engl J Med. 2004 Jul 15. 351(3):241-9. [Medline].
American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 1989 Nov. 84(5):924-36. [Medline].
Amino N, Mori H, Iwatani Y, Tanizawa O, Kawashima M, Tsuge I. High prevalence of transient post-partum thyrotoxicosis and hypothyroidism. N Engl J Med. 1982 Apr 8. 306(14):849-52. [Medline].
Amino N, Tanizawa O, Mori H, Iwatani Y, Yamada T, Kurachi K. Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves' disease. J Clin Endocrinol Metab. 1982 Jul. 55(1):108-12. [Medline].
Anonymous. Dangers of iodides in pregnancy. Lancet. 1970 Jun 13. 1(7659):1273-4. [Medline].
Azizi F. Treatment of post-partum thyrotoxicosis. J Endocrinol Invest. 2006 Mar. 29(3):244-7. [Medline].
Becks GP, Burrow GN. Thyroid disease and pregnancy. Med Clin North Am. 1991 Jan. 75(1):121-50. [Medline].
Belfiore A, Garofalo MR, Giuffrida D, Runello F, Filetti S, Fiumara A. Increased aggressiveness of thyroid cancer in patients with Graves' disease. J Clin Endocrinol Metab. 1990 Apr. 70(4):830-5. [Medline].
Browne-Martin K, Emerson CH. Postpartum thyroid dysfunction. Clin Obstet Gynecol. 1997 Mar. 40(1):90-101. [Medline].
Bungard TJ, Hurlburt M. Management of hypothyroidism during pregnancy. CMAJ. 2007 Apr 10. 176(8):1077-8. [Medline].
Burrow GN. The management of thyrotoxicosis in pregnancy. N Engl J Med. 1985 Aug 29. 313(9):562-5. [Medline].
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000 Feb 28. 160(4):526-34. [Medline].
Casey BM, Dashe JS, Spong CY, McIntire DD, Leveno KJ, Cunningham GF. Perinatal significance of isolated maternal hypothyroxinemia identified in the first half of pregnancy. Obstet Gynecol. 2007 May. 109(5):1129-35. [Medline].
Chattaway JM, Klepser TB. Propylthiouracil versus methimazole in treatment of Graves' disease during pregnancy. Ann Pharmacother. 2007 Jun. 41(6):1018-22. [Medline].
Chopra IJ, Baber K. Treatment of primary hypothyroidism during pregnancy: is there an increase in thyroxine dose requirement in pregnancy?. Metabolism. 2003 Jan. 52(1):122-8. [Medline].
Cooper DS. Clinical practice. Subclinical hypothyroidism. N Engl J Med. 2001 Jul 26. 345(4):260-5. [Medline].
Davis LE, Lucas MJ, Hankins GD, Roark ML, Cunningham FG. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol. 1989 Jan. 160(1):63-70. [Medline].
Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med. 1996 Jul 11. 335(2):99-107. [Medline].
Franklyn JA, Davis JR, Gammage MD, Littler WA, Ramsden DB, Sheppard MC. Amiodarone and thyroid hormone action. Clin Endocrinol (Oxf). 1985 Mar. 22(3):257-64. [Medline].
Furmaniak J, Smith BR. Immunity to the thyroid-stimulating hormone receptor. Springer Semin Immunopathol. 1993. 14(3):309-21. [Medline].
Gerstein HC. How common is postpartum thyroiditis? A methodologic overview of the literature. Arch Intern Med. 1990 Jul. 150(7):1397-400. [Medline].
Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999 Aug 19. 341(8):549-55. [Medline].
Hayslip CC, Fein HG, O'Donnell VM, Friedman DS, Klein TA, Smallridge RC. The value of serum antimicrosomal antibody testing in screening for symptomatic postpartum thyroid dysfunction. Am J Obstet Gynecol. 1988 Jul. 159(1):203-9. [Medline].
Houck JA, Davis RE, Sharma HM. Thyroid-stimulating immunoglobulin as a cause of recurrent intrauterine fetal death. Obstet Gynecol. 1988 Jun. 71(6 Pt 2):1018-9. [Medline].
Jansson R, Bernander S, Karlsson A, Levin K, Nilsson G. Autoimmune thyroid dysfunction in the postpartum period. J Clin Endocrinol Metab. 1984 Apr. 58(4):681-7. [Medline].
Jansson R, Dahlberg PA, Winsa B, Meirik O, Säfwenberg J, Karlsson A. The postpartum period constitutes an important risk for the development of clinical Graves' disease in young women. Acta Endocrinol (Copenh). 1987 Nov. 116(3):321-5. [Medline].
Kvetny J, Poulsen H. Transient hyperthyroxinemia in newborns from women with autoimmune thyroid disease and raised levels of thyroid peroxidase antibodies. J Matern Fetal Neonatal Med. 2006 Dec. 19(12):817-22. [Medline].
Lazarus JH, Ammari F, Oretti R, Parkes AB, Richards CJ, Harris B. Clinical aspects of recurrent postpartum thyroiditis. Br J Gen Pract. 1997 May. 47(418):305-8. [Medline].
Lazarus JH, Kokandi A. Thyroid disease in relation to pregnancy: a decade of change. Clin Endocrinol (Oxf). 2000 Sep. 53(3):265-78. [Medline].
Leung AS, Millar LK, Koonings PP, Montoro M, Mestman JH. Perinatal outcome in hypothyroid pregnancies. Obstet Gynecol. 1993 Mar. 81(3):349-53. [Medline].
Lucas A, Pizarro E, Granada ML, Salinas I, Roca J, Sanmartí A. Postpartum thyroiditis: long-term follow-up. Thyroid. 2005 Oct. 15(10):1177-81. [Medline].
Mandel SJ, Larsen PR, Seely EW, Brent GA. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med. 1990 Jul 12. 323(2):91-6. [Medline].
Martino E, Aghini-Lombardi F, Lippi F, Baschieri L, Safran M, Braverman LE. Twenty-four hour radioactive iodine uptake in 35 patients with amiodarone associated thyrotoxicosis. J Nucl Med. 1985 Dec. 26(12):1402-7. [Medline].
Milham S Jr. Scalp defects in infants of mothers treated for hyperthyroidism with methimazole or carbimazole during pregnancy [letter]. Teratology. 1985 Oct. 32(2):321. [Medline].
Momotani N, Noh J, Oyanagi H, Ishikawa N, Ito K. Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status. N Engl J Med. 1986 Jul 3. 315(1):24-8. [Medline].
Nachum Z, Rakover Y, Weiner E, Shalev E. Graves' disease in pregnancy: prospective evaluation of a selective invasive treatment protocol. Am J Obstet Gynecol. 2003 Jul. 189(1):159-65. [Medline].
Neto LV, De Almeida CA, Da Costa SM, Vaisman M. Prospective evaluation of pregnant women with hypothyroidism: implications for treatment. Gynecol Endocrinol. 2007 Mar. 23(3):138-41. [Medline].
Ordookhani A, Mirmiran P, Walfish PG, Azizi F. Transient neonatal hypothyroidism is associated with elevated serum anti-thyroglobulin antibody levels in newborns and their mothers. J Pediatr. 2007 Mar. 150(3):315-7, 317.e2. [Medline].
Poppe K, Velkeniers B, Glinoer D. Thyroid disease and female reproduction. Clin Endocrinol (Oxf). 2007 Mar. 66(3):309-21. [Medline].
Pruyn SC, Phelan JP, Buchanan GC. Long-term propranolol therapy in pregnancy: maternal and fetal outcome. Am J Obstet Gynecol. 1979 Oct 15. 135(4):485-9. [Medline].
Roti E, Emerson CH. Clinical review 29: Postpartum thyroiditis. J Clin Endocrinol Metab. 1992 Jan. 74(1):3-5. [Medline].
Salvi M, How J. Pregnancy and autoimmune thyroid disease. Endocrinol Metab Clin North Am. 1987 Jun. 16(2):431-44. [Medline].
Simsek M, Mendilcioglu I, Mihci E, Karagüzel G, Taskin O. Prenatal diagnosis and early treatment of fetal goitrous hypothyroidism and treatment results with two-year follow-up. J Matern Fetal Neonatal Med. 2007 Mar. 20(3):263-5. [Medline].
Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA. 1995 Mar 8. 273(10):808-12. [Medline].
[Guideline] Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011 Oct. 21(10):1081-125. [Medline]. [Full Text].
Tachi J, Amino N, Tamaki H, Aozasa M, Iwatani Y, Miyai K. Long term follow-up and HLA association in patients with postpartum hypothyroidism. J Clin Endocrinol Metab. 1988 Mar. 66(3):480-4. [Medline].
Tagami T, Hagiwara H, Kimura T, Usui T, Shimatsu A, Naruse M. The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with graves' disease. Thyroid. 2007 Aug. 17(8):767-72. [Medline].
Tamaki H, Amino N, Aozasa M, Mori M, Tanizawa O, Miyai K. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease. J Clin Endocrinol Metab. 1987 Aug. 65(2):324-30. [Medline].
Degroot LJ, Larsen PR, Henneman G, eds. The Thyroid and Its Diseases. 6th ed. New York, NY: Churchill Livingstone; 1996.
Van Dijke CP, Heydendael RJ, De Kleine MJ. Methimazole, carbimazole, and congenital skin defects. Ann Intern Med. 1987 Jan. 106(1):60-1. [Medline].
Vargas MT, Briones-Urbina R, Gladman D, Papsin FR, Walfish PG. Antithyroid microsomal autoantibodies and HLA-DR5 are associated with postpartum thyroid dysfunction: evidence supporting an autoimmune pathogenesis. J Clin Endocrinol Metab. 1988 Aug. 67(2):327-33. [Medline].
Walfish PG, Chan JY. Post-partum hyperthyroidism. Clin Endocrinol Metab. 1985 May. 14(2):417-47. [Medline].
Weetman AP. Graves' disease. N Engl J Med. 2000 Oct 26. 343(17):1236-48. [Medline].
Widerhorn J, Bhandari AK, Bughi S, Rahimtoola SH, Elkayam U. Fetal and neonatal adverse effects profile of amiodarone treatment during pregnancy. Am Heart J. 1991 Oct. 122(4 Pt 1):1162-6. [Medline].
Wing DA, Millar LK, Koonings PP, Montoro MN, Mestman JH. A comparison of propylthiouracil versus methimazole in the treatment of hyperthyroidism in pregnancy. Am J Obstet Gynecol. 1994 Jan. 170(1 Pt 1):90-5. [Medline].